The effect of cyclooxygenase-2 inhibitors on bone healing

Regional Anesthesia and Pain Medicine

Volumn 28, Issue 5, 2003, Pages 456-465

  Gajraj, Noor M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Dept of Anesth and Pain Management ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; PARECOXIB; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SODIUM CHLORIDE; VALDECOXIB;

ANALGESIA; ANIMAL; BLEEDING; BONE; BONE METABOLISM; BONE REGENERATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FRACTURE HEALING; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE PERFORATION; INTESTINE ULCER; MOUSE; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RAT; RESPIRATION DEPRESSION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0141639888     PISSN: 10987339     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rapm.2003.09.001     Document Type: Article

References (106)

1. Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971;231:232-235.
2. Needleman P, Turk J, Jakschik B, et al. Arachadonic acid metabolism. Annu Rev Biochem 1986;55:69-102.
3. Vane J, Botting R. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-10.
4. Crofford L, Wilder R, Ristimaki A, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: Effects of interleukin-1b, phorbol ester, and corticosteroids. J Clin Invest 1994;93:1095-1101.
5. Seibert K, Masferrer J. Role of inducible cyclooxygenase in inflammation. Receptor 1994;4:17-23.
6. Kang R, Freire-Moar J, Sigal E, Chu C. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 1996;35:711-718.
7. Schwartz J, Chan C, Mukhopadhyay S, et al. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin Pharmacol Ther 1999;65:653-660.
8. Lee S, Soyoola E, Chanmugam P, et al. Selective expression of mitogeninducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-25938.
9. Mitchell J, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-11697.
10. Yamagata K, Andreasson K, Kaufmann W, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 1993;11:371-386.
11. Kaufmann W, Worley P, Pegg J, et al. COX-2, a synaptically induced enzyme is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996;93:2317-2321.
12. Hay C, de Belleroche J. Carrageenan-induced hyperalgesia is associated with increased cyclooxgenase-2 expression in the spinal cord. J Neuroreport 1997;8:1249-1251.
13. Dirig D, Isakson P, Yaksh T. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats. J Pharmacol Exp Ther 1998;285:1031-1038.
14. Yaksh T, Dirig D, Conway C, et al. The acute anti-hyperalgeisc action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001;21:5847-5853.
15. Chandrasekharan NV, Dai H, Roos KLT, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. PNAS 2002;99:13926-13931.
16. Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum? PNAS 2002;99:13371-13373.
17. Wickelgren I. Pain research: Enzyme might relieve research headache. Science 2002;297:1976.
18. Willoughby D, Moore A, Colville-Nash P. COX-1, COX-2, and COX-3 and the future of chronic inflammatory disease. Lancet 2000;355:646-648.
19. Simon L, Weaver A, Graham D, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized contolled trial. JAMA 1999;282:1921-1928.
20. Day R, Morrison B, Luzza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib versus ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-1787.
21. Leese P, Hubbard R, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults. A randomized, controlled trial. J Clin Pharmacol 2000;40:124-132.
22. Greenberg H, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX) did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000;40:1509-1515.
23. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. BMJ 2002;325:619.
24. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
25. Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000;91:1221-1225.
26. Reuben SS, Bhopatkar S, Maciolek H, Joshi W, Sklar J. The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg 2002;94:55-59.
27. Reuben S, Fingeroth R, Krushell R, Maciolek H. Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J Arthroplasty 2002;17:26-31.
28. Reicin A, Brown J, Jove M, et al. Efficacy of single-dose and multidose rolecoxib in the treatment of post-orthopedic surgery pain. Am J Orthop 2001;30:40-48.
29. Camu F, Beecher T, Recker D, Verburg K. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002;9:43-51.
30. Gimbel J, Brugger A, Zhao W, et al. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 2001;23:228-241.
31. Morrison B, Christensen S, Yuan W, et al. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor in post-dental surgery pain: A randomized, controlled trial. Clin Ther 1999;21:943-953.
32. Chang D, Desjardins P, Chen E, et al. Comparison of the analgesic efficacy of rofecoxib and entericcoated diclofenac sodium in the treatment of postoperative dental pain: A randomized, placebo-controlled clinical trial. Clin Ther 2002;24:490-503.
33. Daniels S, Desjardins P, Talwalker S, et al. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J Am Dent Assoc 2002;133:611-621.
34. Fricke J, Varkalis J, Zwillich S, et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther 2002;9:89-97.
35. White P, Klein K, Issioui T, Coloma M. A prospective, randomized, double-blinded, placebo-controlled trial to evaluate the analgesic efficacy and safety of a single dose of acetaminophen and celecoxib for postoperative pain relief in outpatients undergoing ENT surgery [abstract]. Anesth Analg 2001;92:S18.
36. Morrison B, Daniels S, Kotey P, et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial. Obstet Gynecol 1999;94:504-508.
37. Daniels SE, Talwalker S, Torri S, et al. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol 2002;100:350-358.
38. Williams G, Hubbard R, Yu S. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001;23:213-227.
39. Bensen W, Fiechtner J, McMillen J, et al. Treatment of osteoarthritis with celecoxib, a cyclo-oxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc 1999;74:1095-1105.
40. Bensen W, Weaver A, Espinoza L, et al. Valdecoxib, a new COX-2 specific inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis [abstract]. Arth Rheum 2001;44:A1896.
41. McKenna F, Weaver A, Fiechtner J, et al. COX-2 specific inhibitors in the management of osteoarthritis of the knee: A placebo-controlled, randomized, double-blind study. Clin Rheumatol 2001;7:151-159.
42. Geba G, Weaver A, Polis A, et al. Efficacy of rofecoxib, celecoxib, and acetminophen in osteoarthritis of the knee. JAMA 2002;287:64-71.
43. Bensen W, Weaver A, Espinoza L, et al. Efficacy and safety of valdecoxib in treating the symptoms and signs of rheumatoid arthritis: A randomized, controlled comparison with placebo and naproxen. Rheumatology 2002;41:1008-1016.
44. Dougados M, Behier J, Jolchine I, et al. Efficacy of celecoxib, a cycloooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-185.
45. Fiechtner J, Sikes D, Recker D. A double-blind, placebo-controlled dose ranging study to evaluate the efficacy of valdecoxib, a novel COX-2 specific inhibitor, in treating the signs and symptoms of osteoarthritis of the knee [abstract]. European League Against Rheumatism (EULAR), Prague, Czech Republic, June 13-16, 2001.
46. Bertin P, Behier J, Noel E, et al. Efficacy of celecoxib in patients with acute shoulder pain: Randomized double-blind comparison with naproxen [abstract]. Presented at European League Against Rheumatism (EULAR), Prague, Czech Republic, June 13-16, 2001.
47. Kehlet H, Dahl J. The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesth Analg 1993;77:1048-1056.
48. Cheer S, Gao K. Parecoxib (parecoxib sodium). Drugs 2001;61:1133-1141.
49. Hubbard R, Teeny S, Grossman E, et al. Preoperative administration of parecoxib sodium effectively reduced post-operative pain in bunionectomy patients [abstract]. Anesthesiology 2001;95:A812.
50. Patrignani P, Panara M, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271:1705-1712.
51. Warner T, Giuliano I, Vojnovic A, et al. Nonsteroidal drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acd Sci USA 1999;96:7563-7568.
52. Brideau C, Kargman S, Liu S, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. I. Inflamm Res 1996;45:68-74.
53. Young J, Panah S, Satchawatcharaphong C, et al. Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res 1996;45:246-253.
54. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-421.
55. Riendeau D, Percival M, Brideau C, et al. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558-566.
56. Chan C, Boyce S, Brideau C, et al. Rofecoxib (VioxxTM) MK-0966, 4(4′-methylsulfonylphenyl)-3-2-(5h)-furone): A potent, selective and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999;290:551-560.
57. Patti R, Gumired K, Reddanna P. Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: Effect of celecoxib and rofecoxib. Cancer Lett 2002;180:13-21.
58. Blain H, Boileau C, Lapicque F, et al. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol 2002;53:255-265.
59. Waskewich C, Blumenthal R, Li H, et al. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002;62:2029-2033.
60. Dunstan C, Boyce R, Boyce B. Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J Bone Miner Res 1999;14:953-959.
61. Rodan GA. Control of bone formation and resorption: Biological and clinical perspective. J Cell Biochem 1998;30-31:55-61.
62. Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors. J Cell Physiol 1998;175:247-254.
63. Dumont AS, Verma S, Dumont RJ, Hurlbert RJ. Nonsteroidal anti-inflammatory drugs and bone metabolism in spinal fusion surgery: A pharmacological quandary. J Pharmacol Toxicol Methods 2000;43:31-39.
64. Feyen J, van der Wilt G, Moonen P, et al. Stimulation of arachidonic acid metabolism in primary cultures of osteoblast-like cells by hormones and drugs. Prostaglandins 1984;28:769-781.
65. Klein-Nulend J, Burger E, Semeins C, et al. Pulsating fluid flow stimulates prostaglandin release and inducible prostaglandin G/H synthase mRNA expression in primary mouse bone cells. J Bone Miner Res 1997;12:45-51.
66. Wadleigh D, Herschman H. Transcriptional regulation of the cyclooxygenase-2 gene by diverse ligands in murine osteoblasts. Biochem Biophys Res Commun 1999;264:865-870.
67. Thorsen K, Kristoffersson AO, Lerner UH, Lorentzon RP. In situ microdialysis in bone tissue: Stimulation of prostaglandin E2 release by weight-bearing mechanical loading. J Clin Invest 1996;98:2446-2449.
68. Kawaguchi H, Pilbeam C, Harrison J, Raisz L. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop 1995;313:36-46.
69. Jee WSS, Ma YF. The in vivo anabolic actions of prostaglandins in bone. Bone 1997;21:297-304.
70. Turner D, Warson J, Wirt T, et al. The use of ketolorac in lumbar spine surgery: A cost-benefit analysis. J Spinal Disord 1995;8:206-212.
71. Sudmann F, Tveita T, Hald J. Lack of effect of indomethacin on ordered growth of the femur in rats. Acta Orthop Scand 1982;53:43-49.
72. Ho M, Chang J, Wang G. Anti-inflammatory drug effects on bone repair and remodeling in rabbits. Clin Orthop 1995;13:270-278.
73. Sudmann E, Dregelid E, Bessesen A, Morland J. Inhibition of fracture healing by indomethacin in rats. Eur J Clin Invest 1979;9:333-339.
74. Maxy R, Glassman S. The effect of nonsteroidal anti-inflammatory drugs on osteogenesis and spinal fusion. Reg Anesth Pain Med 2001;26:156-158.
75. Tornkvist H, Lindholm T, Netz P, et al. Effect of ibuprofen and indomethacin on bone metabolism reflected in bone strength. Clin Orthop 1984;187:255-259.
76. Bo J, Sudmann E, Marton P. Effect of indomethacin on fracture healing in rats. Acta Orthop Scand 1976;47:588-599.
77. Allen H, Wase A, Bear W. Indomethacin and aspirin: Effect of nonsteroidal anti-inflammatory agents on the rate of fracture repair in the rat. Acta Orthop Scand 1980;51:595-600.
78. Keller J, Bunger C, Andreassen T, Bak B, Lucht U. Bone repair inhibited by indomethacin. Effects on bone metabolism and strength of rabit osteotomies. Acta Orthop Scand 1987;58:379-383.
79. Altman R, Latta L, Keer R, et al. Effect of nonsteroidal anti-inflammatory drugs on fracture healing: A laboratory study in rats. J Orthop Trauma 1995;9:392-400.
80. Pritchett J. Ketorolac prophylaxis against heterotopic ossification after hip replacement. Clin Orthop 1995;314:162-165.
81. Moore K, Goss K, Anglen J. Indomethacin versus radiation therapy for prophylaxis against heterotopic ossification in acetabular fractures. J Bone Joint Surg Br 1998;80:259-263.
82. Giannoudis P, MacDonald D, Matthews S, et al. Nonunion of the femoral diaphysis: The influence of reaming and nonsteroidal anti-inflammatory drugs. J Bone Joint Surg Br 2000;82:655-658.
83. Brown C, Orme T, Richardson H. The rate of pseudoarthrosis (non-union) in patients who are smokers and patients who are nonsmokers: A comparative study. Spine 1986;11:942-943.
84. Frenkel S, Moskovich R, Spivak J, et al. Demineralized bone matrix: enhancement of spinal fusion. Spine 1993;18:1634-1639.
85. Kjaersgaard-Andersen P, Nafei A, Teichert G, et al. Indomethacin for prevention of heterotopic ossification. A randomized controlled study in 41 hip arthroplasties. Acta Orthop Scand 1993;64:639-642.
86. LaPorte DM, Mont MA, Hungerford DS. Proximally porous-coated ingrowth prostheses: Limits of use. Orthopedics 1999;22:1154-1160.
87. Trnka H-J, Zenz P, Zembsch A, Easley M, Ritschl P, Salzer M. Stable bony integration with and without short-term indomethacin prophylaxis. A 5-year follow-up. Arch Orthop Trauma Surg 1999;119:456-460.
88. Wurnig C, Schwameis E, Bitzan P, Kainberger F. Six-year results of a cementless stem with prophylaxis against heterotopic bone. Clin Orthop 1999;361:150-158.
89. Hoikka V, Lindholm TS, Eskola A. Flurbiprofen inhibits heterotopic bone formation in total hip arthroplasty. Arch Orthop Trauma Surg 1990;109:224-226.
90. Moed BR, Resnick RB, Fakhouri AJ, Nallamothu B, Wagner RA. Effect of two nonsteroidal antiinflammatory drugs on heterotopic bone formation in a rabbit model. J Arthroplasty 1994;9:81-87.
91. Cook SD, Thomas KA, Haddad R.J.J. Histologic analysis of retrieved human porous-coated total joint components. Clin Orthop 1988;234:90-101.
92. Dimar J, Ante W, Zhang Y, Glassman S. The effects of nonsteroidal anti-inflammatory drugs on posterior spinal fusions in the rat. Spine 1996;21:1870-1876.
93. Martin G, Boden S, Titus L. Recombinant human bone morphogenetic protein-2 overcomes the inhibitory effect of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), on posterolateral lumbar intertransverse process spine fusion. Spine 1999;24:2188-2194.
94. Deguchi M, Rapoff A, Zdeblick T. Posterolateral fusion for isthmic spondylolisthesis in adults: A study of fusion rate and clinical results. J Spinal Disord 1998;11:459-464.
95. Glassman S, Rose S, Dimar J, et al. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine 1998;23:834-838.
96. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996;97:2672-2679.
97. Jones M, Wang H, Peskar B, Levin E, Itani R. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insights into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-1423.
98. Long J, Lewis S, Kuklo T, Zhu Y, Riew KD. The effect of cyclooxygenase-2 inhibitors on spinal fusion. J Bone Joint Surg Am 2002;84:1763-1768.
99. Mullins B, Copeland S, Weinhold P, et al. Effect on fracture healing in a mouse model. Presented at the 48th Annual Meeting of the Orthopaedic Research Society, Dallas, TX, February 9-12, 2002.
100. Gerstenfeld L, Thiede M, Seibert K. Differential inhibition of fracture healing by non-specific and cyclooxygenase-2 (COX-2) specific non-steroidal antiinflammatory drugs. Presented at the 48th Annual Meeting of the Orthopaedic Research Society, Dallas, TX, February 9-12, 2002.
101. Simon A, Manigrasso M, O'Connor J. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-976.
102. Leonelli S, Goldberg B, Safanda J, et al. The effect of cyclooxygenase 2 (COX-2) inhibitors on bone healing. Presented at the 48th Annual Meeting of the Orthopaedic Research Society. Dallas, TX, February 9-12, 2002.
103. Zhang X, Xing L, Childs L, et al. A critical role of COX-2 in intramembranous and endochondral bone repair. Presented at the 48th Annual Meeting of the Orthopaedic Research Society. Dallas, TX, February 9-12, 2002.
104. Morham S, Langenbach R, Loftin C, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-482.
105. Reuben S, Rizvi A, Steinberg R, Maciolek H. The effect of NSAIDs on spinal fusion. ASRA PD-16, 2002.
106. Goodman S, Ma T, Ikenoue T, et al. COX-2 selective NSAID decreases bone ingrowth in vivo. Presented at the 48th Annual Meeting of the Orthopaedic Research Society. Dallas, TX, February 9-12, 2002.